List of Excipients in Branded Drug DALIRESP

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	DALIRESP	roflumilast	0310-0095	LACTOSE MONOHYDRATE
AstraZeneca Pharmaceuticals LP	DALIRESP	roflumilast	0310-0095	MAGNESIUM STEARATE
AstraZeneca Pharmaceuticals LP	DALIRESP	roflumilast	0310-0095	POVIDONE
AstraZeneca Pharmaceuticals LP	DALIRESP	roflumilast	0310-0095	STARCH, CORN

DALIRESP Excipient Strategy and Commercial Opportunities for Roflumilast Tablets

Last updated: September 25, 2026

DALIRESP is an oral roflumilast tablet approved by the FDA to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The commercial opportunity is primarily in generic 250 mcg and 500 mcg tablets, differentiated starter-dose packaging, lactose-free formulations, improved content uniformity, and lower-cost manufacturing. The product is a small-molecule tablet, not a biologic, so biosimilar competition does not apply. FDA approval is generally pursued through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug, DALIRESP NDA 022522.[1]

What is DALIRESP and how is roflumilast used?

DALIRESP contains roflumilast, a selective phosphodiesterase-4 inhibitor. The FDA-approved dose is 500 mcg orally once daily. A 250 mcg dose may be used for four weeks as a tolerability initiation regimen, but the FDA label states that 250 mcg is not an effective therapeutic dose for COPD.[1]

Attribute	DALIRESP
Active ingredient	Roflumilast
Dosage form	Film-coated oral tablet
Strengths	250 mcg and 500 mcg
FDA application	NDA 022522
Indication	Reduction of COPD exacerbation risk
Administration	Once daily, with or without food
Primary market	Chronic obstructive pulmonary disease
Regulatory competition	Generic ANDA products
Biosimilar relevance	None

The product has a low drug load. That makes excipient selection important because small variations in blend uniformity, segregation, powder flow, and tablet compression can materially affect dose consistency.

What excipients are used in DALIRESP tablets?

The DALIRESP formulation uses conventional immediate-release tablet excipients. The FDA prescribing information identifies lactose monohydrate, corn starch, magnesium stearate, hypromellose, titanium dioxide, talc, and ferric oxide yellow among the inactive ingredients.[1]

The formulation can be analyzed as follows:

Functional role	DALIRESP excipient strategy
Diluent	Lactose monohydrate
Disintegrant or processing aid	Corn starch
Lubricant	Magnesium stearate
Film former	Hypromellose
Opacifier and pigment	Titanium dioxide
Anti-tacking and coating aid	Talc
Colorant	Ferric oxide yellow

The tablet is not dependent on a novel delivery system. Its value is based on accurate low-dose manufacturing, acceptable oral tolerability, chemical stability, and bioequivalence.

How should a generic manufacturer approach the DALIRESP excipient system?

A generic developer has two practical formulation paths.

Reference-matched formulation

The lowest regulatory-risk approach is to reproduce the functional excipient architecture of the reference product:

• Lactose-based dilution
• Starch-assisted disintegration
• Magnesium stearate lubrication
• Hypromellose film coating
• Mineral pigments for color and opacity

This route reduces formulation uncertainty and simplifies comparative dissolution development. It may also reduce the risk that changes in excipient type or level alter roflumilast release.

The principal disadvantages are dependence on lactose supply, possible market limitations for patients avoiding milk-derived excipients, and limited product differentiation.

Differentiated lactose-free formulation

A lactose-free tablet could replace lactose monohydrate with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler. The developer would need to control:

• Blend uniformity at a 250 mcg to 500 mcg drug load
• Powder segregation during transfer and compression
• Tablet weight variation
• Disintegration and dissolution
• Moisture-related stability
• Lubricant sensitivity
• Bioequivalence to DALIRESP

Mannitol could support a more consumer-friendly excipient profile, while microcrystalline cellulose could improve compactability. Dibasic calcium phosphate may improve flow but can create formulation and compatibility issues depending on particle size and moisture exposure.

The commercial benefit is greater than the regulatory benefit. A lactose-free generic may obtain preferred status with certain pharmacy, hospital, or payer systems, but the FDA does not generally grant market exclusivity for routine excipient substitutions.

What are the key technical risks in roflumilast tablet development?

Roflumilast’s microgram-strength dose creates a content-uniformity risk that is more important than the total tablet weight. A developer should prioritize geometric dilution, ordered blending, and validated in-process sampling.

Low-dose content uniformity

The active pharmaceutical ingredient must be distributed consistently through a relatively large excipient mass. Direct blending may be feasible, but a premix or granulation step can provide better control where the API has poor flow or cohesive behavior.

The critical process parameters include:

• API particle-size distribution
• Blend time and order of addition
• Hopper residence time
• Transfer-line design
• Lubrication time
• Compression force
• Tablet weight control

Over-lubrication with magnesium stearate may reduce tablet strength and slow dissolution. Under-lubrication can increase ejection force, sticking, and tooling wear.

Solubility and dissolution

Roflumilast is a potent small molecule administered at a very low dose. Developers should characterize particle size, polymorphic form, wettability, and dissolution across relevant pH conditions. Excipient substitutions that change wetting, disintegration, or hydrophobicity can affect the dissolution profile even when the product remains an immediate-release tablet.

A lactose-free formulation using a more hydrophobic or highly compactable filler may require a revised disintegrant strategy. The formulation should be evaluated against the reference product in multiple dissolution media before pivotal bioequivalence studies.

Coating and appearance

The film coat has limited therapeutic function but has commercial value. Color and imprint clarity support product identification and reduce dispensing errors between 250 mcg and 500 mcg tablets. A generic developer can use a different approved color system, but the tablet should remain readily distinguishable from other strengths.

What commercial opportunities exist for DALIRESP generics?

The most defensible opportunities are low-cost substitution and targeted product differentiation.

1. Standard 500 mcg generic tablets

The 500 mcg tablet is the principal maintenance product. A conventional generic can compete on:

• Acquisition cost
• Reliable supply
• Wholesaler coverage
• Pharmacy substitution
• Payer formulary access
• Packaging efficiency

Because roflumilast is taken once daily, unit demand is tied closely to treated COPD patients rather than high-frequency dosing.

2. 250 mcg initiation packs

The 250 mcg strength has a specific commercial role. It may be prescribed for four weeks to improve tolerability before escalation to 500 mcg.[1] A manufacturer could offer:

• A 28-tablet 250 mcg starter pack
• A starter-plus-maintenance package
• Calendar blister packaging
• Clear transition instructions
• A 250 mcg and 500 mcg co-pack

This is a formulation and packaging opportunity rather than a new indication. The pack could improve adherence and reduce pharmacy coordination, although its value depends on payer coverage and prescribing practices.

3. Lactose-free and excipient-transparent products

A lactose-free product could target patients who avoid lactose or who have excipient sensitivities. The opportunity is commercially narrower than the core generic market, but it may support institutional procurement, specialty pharmacy placement, or a premium authorized-generic strategy.

4. Manufacturing-cost reduction

A developer can reduce cost through:

• Direct compression, if blend uniformity is demonstrated
• Continuous blending
• High-throughput film coating
• Standardized tablet dimensions
• Common tooling across strengths
• Reduced packaging complexity
• Regional manufacturing close to major markets

The low dose makes process capability more important than raw material cost. A low-cost formulation that produces out-of-specification content uniformity will not support a durable commercial position.

What FDA regulatory pathway applies to generic DALIRESP?

A conventional generic would ordinarily use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate that its product has the same active ingredient, dosage form, strength, route of administration, and conditions of use as the reference listed drug, with appropriate pharmaceutical equivalence and bioequivalence.[2]

Key development requirements include:

1. Identification of DALIRESP as the reference listed drug.
2. Pharmaceutical equivalence for 250 mcg and 500 mcg strengths.
3. Comparative dissolution testing.
4. In vivo bioequivalence where required.
5. Stability data supporting the proposed shelf life.
6. Manufacturing controls for low-dose uniformity.
7. Labeling that is consistent with the reference product.

An excipient change does not generally require a 505(b)(2) application if the product remains eligible for ANDA approval. A 505(b)(2) strategy would be more relevant to a materially different dosage form, route, strength, or clinical use.

What is the Orange Book status of DALIRESP?

DALIRESP is listed in the FDA Orange Book as an approved drug product associated with NDA 022522.[3] The Orange Book identifies reference listed drug status, patent information submitted by the NDA holder, and generic-equivalence information.

Patent and exclusivity analysis should distinguish among:

• Regulatory exclusivity
• Listed patents
• Patent-term extensions
• Pediatric exclusivity
• Paragraph IV certifications
• Patent litigation settlements
• Commercial launch restrictions

The core opportunity for a generic depends on whether relevant listed patents remain enforceable, whether a Paragraph IV certification has been filed, and whether any settlement imposes a later launch date. Orange Book entries must be reviewed against current FDA records because listed patents, expiration dates, and certifications can change.

When does DALIRESP lose exclusivity and face generic entry?

DALIRESP’s regulatory exclusivity is separate from patent protection. The FDA approved the product in 2011.[1] Any generic-entry analysis must account for the date of approval, the applicable five-year new-chemical-entity exclusivity period, any three-year exclusivity attached to qualifying supplemental approvals, and patent rights listed in the Orange Book.

The practical generic-entry assessment should use this sequence:

Review step	Commercial question
NDA approval date	Has NCE exclusivity expired?
Orange Book listing	Which patents are listed?
Patent expiration	When can a non-challenging ANDA launch?
Paragraph IV activity	Has a generic applicant challenged a listed patent?
Litigation	Was a 30-month stay triggered?
Settlement	Does the agreement establish a licensed launch date?
FDA approval	Is the ANDA approved but blocked from launch?

A generic manufacturer should not rely on an old patent-expiration date or a secondary database. The controlling analysis requires the live Orange Book, FDA approval records, and applicable court filings.

What formulation patents could affect roflumilast competition?

The principal formulation risk is not necessarily the conventional DALIRESP tablet. Later roflumilast products may pursue different dosage forms or indications.

Oral tablet patents

A conventional immediate-release roflumilast tablet may face composition, process, polymorph, or method-of-use claims if such claims are listed or otherwise enforceable. A generic applicant should assess whether its excipient system, manufacturing process, and product profile fall within any active claim scope.

Topical roflumilast products

Roflumilast is also used in topical products marketed separately from DALIRESP. ZORYVE, marketed by Arcutis Biotherapeutics, is a topical roflumilast product with different dosage forms and indications.[4] Its patents and regulatory exclusivities should not be treated as barriers to an oral DALIRESP generic unless claim scope reaches the oral product or the relevant manufacturing process.

Method-of-use patents

Method claims may cover treatment of COPD, psoriasis, atopic dermatitis, or other conditions. A generic applicant can evaluate labeling strategies, including a section viii statement where legally available, but the product’s proposed labeling must avoid inducing use protected by enforceable method-of-use claims.

Which companies could compete in the DALIRESP generic market?

Competition may come from large generic companies, specialty respiratory manufacturers, and contract development partners. Likely competitive advantages include:

• Existing respiratory sales infrastructure
• Approved oral solid-dose manufacturing
• Low-dose formulation expertise
• Ability to launch both strengths
• Established payer contracting
• United States commercial distribution
• Capacity to manage Paragraph IV litigation

A company with only the 500 mcg strength may compete effectively on price but lose prescribing and pharmacy utility if it cannot supply the 250 mcg initiation regimen. A company offering both strengths, a starter pack, and dependable supply has a stronger commercial proposition.

How strong is the DALIRESP patent estate?

The commercial patent position cannot be rated from the active ingredient alone. Strength depends on the live claims, remaining term, enforceability, Orange Book listing status, and whether a generic design-around is available.

For an oral roflumilast tablet, the relevant strength indicators are:

• Whether composition claims cover the commercial tablet
• Whether claims require a specific excipient combination
• Whether process claims are difficult to avoid
• Whether method claims cover the proposed label
• Whether patent-term adjustment or extension applies
• Whether prior litigation has narrowed claim scope
• Whether multiple independent patents remain enforceable

A standard tablet using different filler, disintegrant, coating, or process parameters may avoid narrow formulation claims. Broad active-ingredient claims, if expired, do not independently block generic entry.

What generic launch scenarios exist for DALIRESP?

Three launch scenarios are commercially plausible.

At-risk launch

A generic launches before final patent resolution after filing a Paragraph IV certification. This can accelerate market entry but exposes the company to damages and injunctive risk if the patent holder prevails.

Licensed launch

A settlement permits launch on an agreed date before the latest patent expiration. The agreement may include supply, distribution, or no-launch provisions. The economic value depends on the number of competing applicants and the negotiated launch date.

Post-expiration launch

A generic enters after all relevant patents and exclusivities expire. This has the lowest litigation risk but may produce lower margins because several ANDA holders can enter simultaneously.

The 250 mcg starter-pack opportunity may remain differentiated after multiple 500 mcg products enter, particularly if manufacturers offer coordinated packaging and consistent supply.

How does DALIRESP compare with other COPD drug opportunities?

DALIRESP is a small-volume, low-dose oral COPD product rather than a high-volume inhaled product. Its development is technically simpler than an inhaled generic because it does not require device equivalence, aerodynamic particle-size testing, or complex in vitro-in vivo correlations.

Factor	DALIRESP generic	Inhaled COPD generic
Dosage form	Oral tablet	Inhaler or nebulized product
Device risk	Low	High
Dose-uniformity risk	High because of microgram dose	Product-specific
Manufacturing complexity	Moderate	Moderate to high
Bioequivalence	Conventional oral approach	Often complex
Excipient differentiation	Practical	Device and formulation dependent
Biosimilar risk	None	None for small molecules
Commercial differentiation	Packaging, excipients, supply	Device, usability, formulation

The tradeoff is market size. Oral roflumilast has a narrower patient population than broad COPD maintenance products, but it can require less development capital and fewer device-related regulatory controls.

Key Takeaways

• DALIRESP is an oral roflumilast tablet approved for reducing COPD exacerbation risk.
• The commercial strengths are 250 mcg and 500 mcg.
• The reference formulation uses lactose monohydrate, corn starch, magnesium stearate, hypromellose, titanium dioxide, talc, and ferric oxide yellow.
• Low-dose content uniformity is the main formulation challenge.
• A reference-matched generic has the lowest development risk.
• A lactose-free formulation offers the clearest excipient-based differentiation.
• A 250 mcg starter pack can improve adherence and create a packaging advantage.
• Generic competition proceeds through the ANDA pathway, subject to Orange Book patents and exclusivities.
• Topical roflumilast products such as ZORYVE are separate products and should not be conflated with DALIRESP.
• Patent and Paragraph IV conclusions require review of the current Orange Book and litigation record before a launch decision.

FAQs About DALIRESP Excipient Strategy and Generic Competition

Can DALIRESP tablets be reformulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, or another suitable diluent, but the applicant must demonstrate acceptable content uniformity, dissolution, stability, and bioequivalence.

Is the 250 mcg DALIRESP tablet commercially important?

Yes. The 250 mcg strength is used as a short-term initiation dose to improve tolerability before escalation to 500 mcg. It is not the labeled therapeutic maintenance dose for COPD.

Does roflumilast require a biosimilar development program?

No. Roflumilast is a chemically synthesized small molecule. A generic applicant generally uses the ANDA pathway rather than the biosimilar pathway.

Can a generic company sell only the 500 mcg strength?

Potentially, but the absence of a 250 mcg initiation product may reduce prescribing convenience and pharmacy coverage. A two-strength portfolio has stronger commercial utility.

Are ZORYVE patents relevant to an oral DALIRESP generic?

Usually not directly. ZORYVE is a topical roflumilast product with different dosage forms, indications, and formulation technology. Relevance depends on the specific patent claims and the proposed generic manufacturing process.

References

1. U.S. Food and Drug Administration. (2023). DALIRESP (roflumilast) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2022). ZORYVE (roflumilast) cream, prescribing information.